Testing effectiveness (Phase 2)Looking for participantsNCT04038502
What this trial is testing
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Who this might be right for
Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development 100